Livagen

Livagen, also known as the KEDA peptide or Livagen bioregulator, is a tetrapeptide with the sequence Lys-Glu-Asp-Ala that has been investigated for its potential bioregulatory properties in hepatocyte research models. This bioregulator peptide is proposed to interact with DNA in liver cells, modulating chromatin structure and gene expression patterns related to hepatic function. The primary mechanism of action centres on Livagen's distinctive ability to induce decondensation of heterochromatin in aging liver cells within research models. This chromatin remodelling effect may reactivate genes that become transcriptionally silenced during the aging process. Studies indicate that this mechanism could potentially restore expression of genes involved in hepatocyte proliferation, oxidative-stress pathway enzyme systems including the cytochrome P450 family, albumin synthesis, and bile acid metabolism pathways. Research investigations have focused on Livagen's potential to support hepatocyte function through proposed chromatin decondensation in aging liver models. Laboratory studies suggest the peptide may contribute to normalisation of liver gene expression patterns and support liver regenerative capacity in research settings. Additionally, theoretical improvements in oxidative-stress pathway pathways have been proposed based on the peptide's chromatin modulation effects. The current evidence base for Livagen consists primarily of preclinical studies, with research predominantly conducted by the Khavinson research group. In vitro investigations have demonstrated that the Lys-Glu-Asp-Ala peptide can induce chromatin decondensation in hepatocyte cultures derived from aging animal models. Animal studies have shown some evidence of improved liver function markers, though controlled human clinical trials have not been published to date, placing the evidence grade at level D.